{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:25:30Z","timestamp":1788366330408,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ethnopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jep.2023.116734","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:31:36Z","timestamp":1686141096000},"page":"116734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials"],"prefix":"10.1016","volume":"316","author":[{"given":"Jixin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jep.2023.116734_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.6-suppl_2-1","article-title":"Introduction: the history of arsenic trioxide in cancer therapy","volume":"6","author":"Antman","year":"2001","journal-title":"Oncol."},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib2","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-09-2590","article-title":"A phase I study of 5-fluorouracil\/leucovorin and arsenic trioxide for patients with refractory\/relapsed colorectal carcinoma","volume":"16","author":"Ardalan","year":"2010","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Base. Healthc."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jep.2023.116734_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jclinepi.2017.10.002","article-title":"Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms","volume":"93","author":"Bougioukas","year":"2018","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib6","first-page":"221","article-title":"Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer biomarkers","volume":"28","author":"Cai","year":"2020","journal-title":"section A of Disease markers"},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12011-017-0975-5","article-title":"Dihydroartemisinin sensitizes human lung adenocarcinoma A549 cells to arsenic trioxide via apoptosis","volume":"179","author":"Chen","year":"2017","journal-title":"Biol. Trace Elem. Res."},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1142\/S0192415X10008524","article-title":"Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway","volume":"38","author":"Chen","year":"2010","journal-title":"Am. J. Chin. Med."},{"issue":"5","key":"10.1016\/j.jep.2023.116734_bib9","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/cancers15051471","article-title":"Hedgehog-GLI and notch pathways sustain chemoresistance and invasiveness in colorectal cancer and their inhibition restores chemotherapy efficacy","volume":"15","author":"Citarella","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/not021","article-title":"A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood","volume":"15","author":"Cohen","year":"2013","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","article-title":"Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system","volume":"93","author":"Dai","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/02656736.2022.2093995","article-title":"Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2","volume":"39","author":"Dong","year":"2022","journal-title":"Int. J. Hyperther. : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group"},{"issue":"4\u20135","key":"10.1016\/j.jep.2023.116734_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide - an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev."},{"key":"10.1016\/j.jep.2023.116734_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.omto.2019.01.006","article-title":"Skp2 expression is inhibited by arsenic trioxide through the upregulation of miRNA-330-5p in pancreatic cancer cells","volume":"12","author":"Gao","year":"2019","journal-title":"Molecular therapy oncolytics"},{"issue":"4","key":"10.1016\/j.jep.2023.116734_bib15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3892\/ol.2017.5679","article-title":"Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity","volume":"13","author":"Gao","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jep.2023.116734_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.fct.2017.04.035","article-title":"Chrysin and silibinin sensitize human glioblastoma cells for arsenic trioxide","volume":"105","author":"G\u00fclden","year":"2017","journal-title":"Food Chem. Toxicol. : an international journal published for the British Industrial Biological Research Association"},{"issue":"7650","key":"10.1016\/j.jep.2023.116734_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jep.2023.116734_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3428370","article-title":"A meta-analysis of arsenic trioxide combined with transcatheter arterial chemoembolization for treatment of primary hepatic carcinoma","author":"He","year":"2016","journal-title":"Evidence-Based Complementary And Alternative Medicine 2016"},{"issue":"7414","key":"10.1016\/j.jep.2023.116734_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"issue":"8","key":"10.1016\/j.jep.2023.116734_bib20","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s00204-020-02772-9","article-title":"Biotransformation of arsenic and toxicological implication of arsenic metabolites","volume":"94","author":"Hirano","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00775-018-1537-9","article-title":"Arsenic trioxide: insights into its evolution to an anticancer agent","volume":"23","author":"Hoonjan","year":"2018","journal-title":"J. Biol. Inorg. Chem. : JBIC : a publication of the Society of Biological Inorganic Chemistry"},{"key":"10.1016\/j.jep.2023.116734_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12935-020-01341-5","article-title":"Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress","volume":"20","author":"Hu","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"5","key":"10.1016\/j.jep.2023.116734_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/02656730600722685","article-title":"A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer","volume":"22","author":"Huilgol","year":"2006","journal-title":"Int. J. Hyperther. : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group"},{"issue":"10","key":"10.1016\/j.jep.2023.116734_bib24","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2003-03-0772","article-title":"Vitamin C protects HL60 and U266 cells from arsenic toxicity","volume":"105","author":"Karasavvas","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib25","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/10717544.2020.1856219","article-title":"Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal","volume":"27","author":"Kong","year":"2020","journal-title":"Drug Deliv."},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/tox.23299","article-title":"Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells","volume":"36","author":"Kumar","year":"2021","journal-title":"Environ. Toxicol."},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11060-017-2469-x","article-title":"A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas","volume":"133","author":"Kumthekar","year":"2017","journal-title":"Journal of neuro-oncology"},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/leu.2011.245","article-title":"Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia","volume":"26","author":"Lengfelder","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib29","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3892\/ol.2017.6646","article-title":"Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma","volume":"14","author":"Leung","year":"2017","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.jep.2023.116734_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3727\/096504021X16184815905096","article-title":"Excellent early outcomes of combined chemotherapy with arsenic trioxide for stage 4\/M neuroblastoma in children: a multicenter nonrandomized controlled trial","volume":"28","author":"Li","year":"2021","journal-title":"Oncology research"},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib31","first-page":"1347","article-title":"Arsenic trioxide for incipient stage acute promyelocytic leukemia: a meta-analysis","volume":"13","author":"Li","year":"2013","journal-title":"Chin. J. Evidence-Based Med."},{"key":"10.1016\/j.jep.2023.116734_bib32","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.7717\/peerj.962","article-title":"Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line","volume":"3","author":"Li","year":"2015","journal-title":"PeerJ"},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib33","doi-asserted-by":"crossref","first-page":"e3159","DOI":"10.1038\/cddis.2017.482","article-title":"Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I","volume":"8","author":"Ling","year":"2017","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jgh.13789","article-title":"Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: a meta-analysis","volume":"32","author":"Lv","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.jep.2023.116734_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158760","article-title":"All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis","volume":"11","author":"Ma","year":"2016","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.jep.2023.116734_bib36","first-page":"3893","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2402599","article-title":"Clinical activity of arsenic trioxide for the treatment of multiple myeloma","volume":"16","author":"Munshi","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jep.2023.116734_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069466","article-title":"Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation","volume":"8","author":"Nakamura","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2004.02.013","article-title":"Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide","volume":"60","author":"Ning","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jep.2023.116734_bib40","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.taap.2007.09.020","article-title":"Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells","volume":"226","author":"Paul","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib42","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/advances\/nmac087","article-title":"Diet and esophageal cancer risk: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"13","author":"Qin","year":"2022","journal-title":"Advances in nutrition (Bethesda, Md"},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11427-013-4487-z","article-title":"A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Science China","volume":"56","author":"Rao","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.jep.2023.116734_bib44","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"Br. Med. J."},{"issue":"5","key":"10.1016\/j.jep.2023.116734_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ctrv.2009.04.007","article-title":"The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review","volume":"35","author":"R\u00f6llig","year":"2009","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jep.2023.116734_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594129","article-title":"UK experience of an alternative ATO dosing regimen in APL","volume":"10","author":"Russell","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11033-022-08042-4","article-title":"Andrographolide protects against doxorubicin-and arsenic trioxide-induced toxicity in cardiomyocytes","volume":"50","author":"Safaeian","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"15","key":"10.1016\/j.jep.2023.116734_bib48","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jep.2023.116734_bib49","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"Amstar 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Br. Med. J."},{"issue":"24","key":"10.1016\/j.jep.2023.116734_bib50","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1080\/15384101.2017.1387699","article-title":"Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells","volume":"16","author":"Shi","year":"2017","journal-title":"Cell Cycle"},{"issue":"18","key":"10.1016\/j.jep.2023.116734_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010613","article-title":"Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: a systematic review and meta-analysis","volume":"97","author":"Song","year":"2018","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-022-01315-2","article-title":"hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype","volume":"15","author":"Su","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jep.2023.116734_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.envint.2016.07.020","article-title":"Mechanisms of arsenic disruption on gonadal, adrenal and thyroid endocrine systems in humans: a review","volume":"95","author":"Sun","year":"2016","journal-title":"Environ. Int."},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib54","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.jep.2023.116734_bib55","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.032","article-title":"Acute promyelocytic leukemia (APL): comparison between children and adults","volume":"6","author":"Testi","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jep.2023.116734_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2020.00123","article-title":"Ascorbic acid sensitizes colorectal carcinoma to the cytotoxicity of arsenic trioxide via promoting reactive oxygen species-dependent apoptosis and pyroptosis","volume":"11","author":"Tian","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-022-00753-y","article-title":"An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-019-1676-0","article-title":"Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF\/MCM7 complex","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.21037\/tcr.2020.02.17","article-title":"Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.jep.2023.116734_bib60","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metallomics : integrated biometal science"},{"issue":"Suppl. 2","key":"10.1016\/j.jep.2023.116734_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_2-3","article-title":"History of the development of arsenic derivatives in cancer therapy","volume":"6","author":"Waxman","year":"2001","journal-title":"Oncol."},{"key":"10.1016\/j.jep.2023.116734_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.jep.2023.116734_bib63","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4161\/cbt.25937","article-title":"Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment","volume":"14","author":"Xu","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.jep.2023.116734_bib64","first-page":"2695","article-title":"Evaluation on efficacy and safety of arsenic trioxide plus transcatheter arterial chemoembolization versus transcatheter arterial chemoembolization alone forUnresectable primary liver cancer","volume":"18","author":"Yang","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.jep.2023.116734_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6243165","article-title":"Application of arsenic trioxide-based combined sequential chemotherapy in recurrent resistant and refractory ovarian cancers: a single-center, open phase II clinical study","volume":"2022","author":"Yang","year":"2022","journal-title":"Journal of oncology"},{"key":"10.1016\/j.jep.2023.116734_bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-3-28","article-title":"Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells","volume":"3","author":"Yedjou","year":"2010","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.jep.2023.116734_bib67","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/pharmaceutics14040743","article-title":"Current advances of nanomedicines delivering arsenic trioxide for enhanced tumor therapy","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jep.2023.116734_bib68","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s13277-014-2839-3","article-title":"Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation","volume":"36","author":"Zhai","year":"2015","journal-title":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"4","key":"10.1016\/j.jep.2023.116734_bib69","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s10753-018-0775-x","article-title":"Double-sided personality: effects of arsenic trioxide on inflammation","volume":"41","author":"Zhang","year":"2018","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3892\/etm.2020.9299","article-title":"Effect of arsenic trioxide on cervical cancer and its mechanisms","volume":"20","author":"Zhang","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib71","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1002\/ctm2.335","article-title":"Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"20","key":"10.1016\/j.jep.2023.116734_bib72","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1039\/D2BM01039A","article-title":"Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia by targeting the AP4\/galectin-1 pathway","volume":"10","author":"Zhao","year":"2022","journal-title":"Biomater. Sci."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2013.08.022","article-title":"Combination of arsenic trioxide and chemotherapy in small cell lung cancer","volume":"82","author":"Zheng","year":"2013","journal-title":"Lung Cancer"},{"issue":"1\u20132","key":"10.1016\/j.jep.2023.116734_bib74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11010-014-2027-1","article-title":"Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide","volume":"392","author":"Zhong","year":"2014","journal-title":"Mol. Cell. Biochem."},{"issue":"33","key":"10.1016\/j.jep.2023.116734_bib75","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib76","first-page":"118","article-title":"Systematic review of all-trans retinoic acid and arsenic trioxide in treating acute promyeloytic leukemia","volume":"30","author":"Yue","year":"2014","journal-title":"Chin J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jep.2023.116734_bib77","first-page":"912","article-title":"Effectiveness of inductive treatment with arsenic trioxide for acute promyelocytic leukemia: a systematic review","volume":"5","author":"Lixia","year":"2005","journal-title":"Chin. J. Evidence-Based Med."},{"key":"10.1016\/j.jep.2023.116734_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3428370","article-title":"A meta-analysis of arsenic trioxide combined with transcatheter arterial chemoembolization for treatment of primary hepatic carcinoma","author":"He","year":"2016","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.jep.2023.116734_bib79","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/OTT.S67165","article-title":"Arsenic trioxide-based therapy in relapsed\/refractory multiple myeloma patients: a meta-analysis and systematic review","volume":"7","author":"He","year":"2014","journal-title":"OncoTargets Ther."},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib80","first-page":"1347","article-title":"Arsenic trioxide for incipient stage acute promyelocytic leukemia: a meta-analysis","volume":"13","author":"Li","year":"2013","journal-title":"Chin. J. Evidence-Based Med."},{"issue":"22","key":"10.1016\/j.jep.2023.116734_bib81","first-page":"4119","article-title":"Meta-analysis of the effectiveness of all-trans retinoic acid with and without arsenic trioxide in the treatment of acute promyelocytic leukemia","volume":"40","author":"Yajie","year":"2013","journal-title":"Mod. Prev. Med."},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib82","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jgh.13789","article-title":"Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: a meta-analysis","volume":"32","author":"Lv","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.jep.2023.116734_bib83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000369242","article-title":"Insights into the all-trans-retinoic acid and arsenic trioxide combination treatment for acute promyelocytic leukemia: a meta-analysis","volume":"134","author":"Ma","year":"2015","journal-title":"Acta Haematol."},{"issue":"7","key":"10.1016\/j.jep.2023.116734_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158760","article-title":"All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis","volume":"11","author":"Ma","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jep.2023.116734_bib85","volume":"vol. 19","author":"Sasijareonrat","year":"2020"},{"issue":"6","key":"10.1016\/j.jep.2023.116734_bib86","first-page":"523","article-title":"Arsenic trioxide combined with TACE for the treatment of advanced primary hepatic carcinoma: meta-analysis of its curative effect","volume":"27","author":"Dong","year":"2018","journal-title":"J. Intervent. Radiol."},{"issue":"18","key":"10.1016\/j.jep.2023.116734_bib87","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010613","article-title":"Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: a systematic review and meta-analysis","volume":"97","author":"Song","year":"2018","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib88","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.leukres.2011.06.002","article-title":"The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.jep.2023.116734_bib89","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3736\/jcim20091102","article-title":"Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis","volume":"7","author":"Shuangnian","year":"2009","journal-title":"J. Chin. Integr. Med."},{"issue":"21","key":"10.1016\/j.jep.2023.116734_bib90","first-page":"2098","article-title":"Arsenic trioxide vs all-trans retinoic acid to treat acute promyeloctic leukemia: a systematic comparative review","volume":"31","author":"Shuangnian","year":"2009","journal-title":"Acta Acad Med Militaris Tertiae"},{"issue":"9","key":"10.1016\/j.jep.2023.116734_bib91","article-title":"Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis","volume":"7","author":"Shuangnian","year":"2009","journal-title":"J. Chin. Integr. Med."},{"issue":"10","key":"10.1016\/j.jep.2023.116734_bib92","first-page":"2695","article-title":"Evaluation on efficacy and safety of arsenic trioxide plus transcatheter arterial chemoembolization versus transcatheter arterial chemoembolization alone forUnresectable primary liver cancer","volume":"18","author":"Yang","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"}],"container-title":["Journal of Ethnopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874123006025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874123006025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:39:57Z","timestamp":1759945197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378874123006025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":92,"alternative-id":["S0378874123006025"],"URL":"https:\/\/doi.org\/10.1016\/j.jep.2023.116734","relation":{},"ISSN":["0378-8741"],"issn-type":[{"value":"0378-8741","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Ethnopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jep.2023.116734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116734"}}